U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H22F3N5O2S
Molecular Weight 441.4723
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ALPELISIB

SMILES

Cc1c(-c2ccnc(c2)C(C)(C)C(F)(F)F)sc(n1)N=C(N3CCC[C@@]3([H])C(=N)O)O

InChI

InChIKey=STUWGJZDJHPWGZ-LBPRGKRZSA-N
InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1

HIDE SMILES / InChI
Alpelisib (BYL719) is a PI3Kα-selective inhibitor. PI3K-AKT-mTOR pathway is frequently activated in cancer, therefore investigational PI3K inhibitor alpelisib is considered to be effective as an anticancer agent and has been in clinical development by Novartis. Alpelisib have demonstrated activity in preclinical models of solid tumors and had favorable tolerability profiles, with the most common adverse events consistent with “on-target” inhibition of PI3K in early clinical studies. There are ongoing clinical trials of alpelisib in a range of cancer types, including breast cancer, head and neck squamous cell carcinoma, non-small cell lung carcinoma, lymphoma, and glioblastoma multiforme. Combination therapy with other chemo therapeutics may be preferable.

Originator

Curator's Comment:: # Novartis

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P42336
Gene ID: 5290.0
Gene Symbol: PIK3CA
Target Organism: Homo sapiens (Human)
5.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2480 ng/mL
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALPELISIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
33224 ng × h/mL
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALPELISIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.5 h
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALPELISIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
11%
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
ALPELISIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 48.0 years (range: 24-72 years)
n = 7
Health Status: unhealthy
Age Group: 48.0 years (range: 24-72 years)
Sex: M+F
Population Size: 7
Sources:
DLT: Maculopapular rash, Conjunctivitis...
Dose limiting toxicities:
Maculopapular rash (grade 3, 2 patients)
Conjunctivitis (grade 2, 1 patient)
Sources:
350 mg 1 times / day steady, oral
Studied dose
Dose: 350 mg, 1 times / day
Route: oral
Route: steady
Dose: 350 mg, 1 times / day
Sources:
unhealthy, 54.5 years (range: 31-72 years)
n = 8
Health Status: unhealthy
Age Group: 54.5 years (range: 31-72 years)
Sex: M+F
Population Size: 8
Sources:
DLT: Tumor infection...
Dose limiting toxicities:
Tumor infection (grade 4, 1 patient)
Sources:
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Disc. AE: Hyperglycemia, Rash...
AEs leading to
discontinuation/dose reduction:
Hyperglycemia (grade 3-4, 4.2%)
Rash (grade 3-4, 1.1%)
Diarrhea (grade 3-4, 0.4%)
Fatigue (grade 3-4, 1.1%)
Nausea (grade 3-4, 0.4%)
Hyperglycaemia (grade 3-4, 31.3%)
Diarrhoea (grade 3-4, 5.6%)
Rash (grade 3-4, 9.2%)
Rash maculo-papular (grade 3-4, 8.8%)
Stomatitis (grade 3-4, 2.1%)
Mucosal inflammation (grade 3-4, 1.4%)
Nausea (grade 3-4, 1.4%)
Lipase increased (grade 3-4, 3.5%)
Pyrexia (grade 3-4, 0.7%)
Fatigue (grade 3-4, 1.4%)
Pruritus (grade 3-4, 0.4%)
Vomiting (grade 3-4, 0.4%)
Asthenia (grade 3-4, 1.1%)
Decreased appetite (grade 3-4, 0.4%)
Alanine aminotransferase increased (grade 3-4, 2.1%)
Sources: Page: p. 138
450 mg 1 times / day steady, oral
Highest studied dose
Dose: 450 mg, 1 times / day
Route: oral
Route: steady
Dose: 450 mg, 1 times / day
Sources: Page: p. 68
unhealthy
Health Status: unhealthy
Condition: advanced solid malignancies
Sources: Page: p. 68
400 mg 1 times / day steady, oral
MTD
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources: Page: p. 76, 87
unhealthy
n = 33
Health Status: unhealthy
Condition: advanced solid malignancies
Population Size: 33
Sources: Page: p. 76, 87
AEs

AEs

AESignificanceDosePopulation
Conjunctivitis grade 2, 1 patient
DLT
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 48.0 years (range: 24-72 years)
n = 7
Health Status: unhealthy
Age Group: 48.0 years (range: 24-72 years)
Sex: M+F
Population Size: 7
Sources:
Maculopapular rash grade 3, 2 patients
DLT
400 mg 1 times / day steady, oral
Studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 48.0 years (range: 24-72 years)
n = 7
Health Status: unhealthy
Age Group: 48.0 years (range: 24-72 years)
Sex: M+F
Population Size: 7
Sources:
Tumor infection grade 4, 1 patient
DLT
350 mg 1 times / day steady, oral
Studied dose
Dose: 350 mg, 1 times / day
Route: oral
Route: steady
Dose: 350 mg, 1 times / day
Sources:
unhealthy, 54.5 years (range: 31-72 years)
n = 8
Health Status: unhealthy
Age Group: 54.5 years (range: 31-72 years)
Sex: M+F
Population Size: 8
Sources:
Decreased appetite grade 3-4, 0.4%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Diarrhea grade 3-4, 0.4%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Nausea grade 3-4, 0.4%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Pruritus grade 3-4, 0.4%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Vomiting grade 3-4, 0.4%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Pyrexia grade 3-4, 0.7%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Asthenia grade 3-4, 1.1%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Fatigue grade 3-4, 1.1%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Rash grade 3-4, 1.1%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Fatigue grade 3-4, 1.4%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Mucosal inflammation grade 3-4, 1.4%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Nausea grade 3-4, 1.4%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Alanine aminotransferase increased grade 3-4, 2.1%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Stomatitis grade 3-4, 2.1%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Lipase increased grade 3-4, 3.5%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Hyperglycaemia grade 3-4, 31.3%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Hyperglycemia grade 3-4, 4.2%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Diarrhoea grade 3-4, 5.6%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Rash maculo-papular grade 3-4, 8.8%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Rash grade 3-4, 9.2%
Disc. AE
300 mg 1 times / day steady, oral
Recommended
Dose: 300 mg, 1 times / day
Route: oral
Route: steady
Dose: 300 mg, 1 times / day
Co-administed with::
fulvestrant(500 mg was administered intramuscularly on Cycle 1, Day 1 and 15 and then at Day 1 of each 28-day cycle during treatment phase)
Sources: Page: p. 138
unhealthy, 63 years (range: 25 - 92 years)
n = 284
Health Status: unhealthy
Age Group: 63 years (range: 25 - 92 years)
Sex: M+F
Population Size: 284
Sources: Page: p. 138
Overview

Overview

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
low [Ki 1.38 uM]
no [EC50 26 uM]
no [EC50 34 uM]
no [EC50 66 uM]
no [Ki 101.5 uM]
no [Ki 139.6 uM]
no [Ki 190.8 uM]
no [Ki 20.9 uM]
no [Ki 215.5 uM]
no [Ki 29.4 uM]
no [Ki 36 uM]
no [Ki 40 uM]
no [Ki 42.4 uM]
no [Ki 49.6 uM]
no [Ki 74.5 uM]
no [Ki 77.6 uM]
no [Ki 8.59 uM]
no [Ki 91.6 uM]
no [Ki >175 uM]
yes [EC50 2.2 uM]
yes [EC50 3 uM]
yes [Ki 96.7 uM]
yes
yes
Drug as victimTox targets
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.
2013 Jul 1
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design.
2016
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
2016
Patents

Sample Use Guides

Alpelisib (300 mg once daily) in combination with fulvestrant (500 mg; intramuscular injection on day 1 and day 15 of cycle 1, and then day 1 of each subsequent 28-day cycle) for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment.
Route of Administration: Oral
Overexpression of FGFR1 in ER+/PIK3CA mutant breast cancer cells attenuated the response to alpelisib in vitro .
Name Type Language
ALPELISIB
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
(2S)-N1-(4-METHYL-5-(1-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)PYRIDIN-4-YL)-1,3-THIAZOL-2-YL)PYRROLIDINE-1,2-DICARBOXAMIDE
Systematic Name English
NVP-BYL719
Code English
ALPELISIB [ORANGE BOOK]
Common Name English
ALPELISIB [MI]
Common Name English
BYL719
Code English
ALPELISIB [INN]
Common Name English
1,2-PYRROLIDINEDICARBOXAMIDE, N1-(4-METHYL-5-(2-(2,2,2-TRIFLUORO-1,1-DIMETHYLETHYL)-4-PYRIDINYL)-2-THIAZOLYL)-, (2S)-
Systematic Name English
ALPELISIB [WHO-DD]
Common Name English
PIQRAY
Brand Name English
ALPELISIB [USAN]
Common Name English
BYL-719
Common Name English
(S)-PYRROLIDINE-1,2-DICARBOXYLIC ACID 2-AMIDE 1-(4-METHYL-5-(2-(2,2,2-TRIFLUORO-1,1-DIMETHYLETHYL)-PYRIDIN-4-YL)THIAZOL-2-YL)AMIDE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2152
Created by admin on Sat Jun 26 03:04:30 UTC 2021 , Edited by admin on Sat Jun 26 03:04:30 UTC 2021
NCI_THESAURUS C129825
Created by admin on Sat Jun 26 03:04:30 UTC 2021 , Edited by admin on Sat Jun 26 03:04:30 UTC 2021
FDA ORPHAN DRUG 710819
Created by admin on Sat Jun 26 03:04:30 UTC 2021 , Edited by admin on Sat Jun 26 03:04:30 UTC 2021
Code System Code Type Description
RXCUI
2169285
Created by admin on Sat Jun 26 03:04:30 UTC 2021 , Edited by admin on Sat Jun 26 03:04:30 UTC 2021
PRIMARY
DRUG BANK
DB12015
Created by admin on Sat Jun 26 03:04:30 UTC 2021 , Edited by admin on Sat Jun 26 03:04:30 UTC 2021
PRIMARY
PUBCHEM
56649450
Created by admin on Sat Jun 26 03:04:30 UTC 2021 , Edited by admin on Sat Jun 26 03:04:30 UTC 2021
PRIMARY
DRUG CENTRAL
5328
Created by admin on Sat Jun 26 03:04:30 UTC 2021 , Edited by admin on Sat Jun 26 03:04:30 UTC 2021
PRIMARY
EPA CompTox
1217486-61-7
Created by admin on Sat Jun 26 03:04:30 UTC 2021 , Edited by admin on Sat Jun 26 03:04:30 UTC 2021
PRIMARY
MERCK INDEX
M12147
Created by admin on Sat Jun 26 03:04:30 UTC 2021 , Edited by admin on Sat Jun 26 03:04:30 UTC 2021
PRIMARY
NCI_THESAURUS
C94214
Created by admin on Sat Jun 26 03:04:30 UTC 2021 , Edited by admin on Sat Jun 26 03:04:30 UTC 2021
PRIMARY
INN
9833
Created by admin on Sat Jun 26 03:04:30 UTC 2021 , Edited by admin on Sat Jun 26 03:04:30 UTC 2021
PRIMARY
EVMPD
SUB180707
Created by admin on Sat Jun 26 03:04:30 UTC 2021 , Edited by admin on Sat Jun 26 03:04:30 UTC 2021
PRIMARY
ChEMBL
CHEMBL2396661
Created by admin on Sat Jun 26 03:04:30 UTC 2021 , Edited by admin on Sat Jun 26 03:04:30 UTC 2021
PRIMARY
CAS
1217486-61-7
Created by admin on Sat Jun 26 03:04:30 UTC 2021 , Edited by admin on Sat Jun 26 03:04:30 UTC 2021
PRIMARY
FDA UNII
08W5N2C97Q
Created by admin on Sat Jun 26 03:04:30 UTC 2021 , Edited by admin on Sat Jun 26 03:04:30 UTC 2021
PRIMARY